<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The cytotoxic effect of the new potential intercalating anticancer drug oracin was studied on Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell line that overexpressed bcl-2 (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> bcl-2) and a control transfectant without the bcl-2 gene (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> SV2) </plain></SENT>
<SENT sid="1" pm="."><plain>Oracin showed a marked <z:chebi fb="0" ids="35610">cytostatic</z:chebi> effect on both <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> SV2 and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> bcl-2 cells </plain></SENT>
<SENT sid="2" pm="."><plain>IC50, as measured by the <z:chebi fb="0" ids="53233">MTT</z:chebi> assay, was approx </plain></SENT>
<SENT sid="3" pm="."><plain>5-times greater for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> bcl-2 cells (5.0 micromol/l) than for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> SV2 cells (1.0 micromol/l) </plain></SENT>
<SENT sid="4" pm="."><plain>There was no significant increase in <z:mpath ids='MPATH_3'>apoptosis</z:mpath> after 24 h of treatment with oracin (1.0 micromol/l) in both cell lines </plain></SENT>
<SENT sid="5" pm="."><plain>However, after 48 h from the removal of oracin in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> SV2 culture the levels of apoptotic and secondary necrotic cells increased to 20 and 37%, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> bcl-2 cells treated in a similar manner showed only basal levels of apoptotic and secondary necrotic cells </plain></SENT>
<SENT sid="7" pm="."><plain>Analysis of the cell cycle profiles showed a significant increase of S and G2/M phases of the cell cycle in both cell lines after 6 h of drug treatment (1.0 micromol/l) </plain></SENT>
<SENT sid="8" pm="."><plain>The cells were arrested in G2/M phase of the cell cycle after 24 h, with no significant changes in cell viability </plain></SENT>
<SENT sid="9" pm="."><plain>After 72 h, the viable <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> SV2 cells were still in G2/M, however, the viability of this culture had fallen to approx </plain></SENT>
<SENT sid="10" pm="."><plain>5% </plain></SENT>
<SENT sid="11" pm="."><plain>Flow cytometry analysis of the DNA content revealed the presence of a 'sub-G2' region, which represented the apoptotic cells </plain></SENT>
<SENT sid="12" pm="."><plain>The <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> SV2 cells died after 72 h while they were in the G2/M phase </plain></SENT>
<SENT sid="13" pm="."><plain>Although the treated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> bcl-2 cells were similarly arrested in the G2/M phase, they nevertheless remained with a relatively high viability (68%) </plain></SENT>
</text></document>